Cell Death in Immune Thrombocytopenia: Novel Insights and Perspectives  by von Gunten, Stephan et al.
Cell Death in Immune Thrombocytopenia: Novel Insights
and Perspectives
Stephan von Gunten, Marc Wehrli, and Hans-Uwe SimonImmune thrombocytopenia (ITP) is a complex disease. The pathogenic and clinical hetero-0037-1963
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Seminarsgeneity of ITP is reflected by reports on variability in patient history and treatment response, in
concert with recent evidence from mechanistic studies. Programmed cell death (PCD)
pathways are thought to play a peculiar role in the megakaryocyte lineage in terms of
hemostasis and the generation and function of megakaryocytes and platelets; unbalanced
genetic or environmental disturbances of these tightly regulated pathways may cause
thrombocytopenia. Dysregulated PCD has also been linked to peripheral platelet destruction,
intramedullary apoptosis, and inefficient thrombopoiesis in ITP. In this article, we discuss novel
and controversial findings on the role of PCD in the megakaryocyte lineage and their potential
implications in terms of pathogenesis, diagnosis, and treatment of ITP.
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n the course of his famous experiment in 1950,
Dr William Harrington developed severe throm-
bocytopenia after infusion with blood from a
patient with idiopathic thrombocytopenic purpura,
now referred to as immune thrombocytopenia (ITP).
In the following years Harrington et al1 and Shulman
et al2 provided evidence that a humoral factor is
responsible for the diminished numbers of circulat-
ing platelets in ITP. Based on these seminal studies,
the concept was adopted that the thrombocytopenia
in ITP is caused by autoantibodies that mediate
clearance of circulating platelets by phagocytes of
the reticuloendothelial system, predominantly in
spleen and liver.3 However, in the 1980s Ballem
et al4 and many other laboratories showed in kinetic
studies that the thrombocytopenia in ITP not only
results from peripheral platelet destruction but also
from depressed platelet generation in the bone
marrow. Platelets5 and their precursors, megakaryo-
cytes,6 both contain functional pathways of pro-
grammed cell death (PCD), and signs of
pathologically enhanced or aberrant cell death have
been found in ITP platelets and megakaryocytes.5,7blished by Elsevier Inc.
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Open access under CC BY-NC-ND license.Biochemical pathways of PCD regulate platelet and
megakaryocyte lifespan, and distinct PCD pathways
seem to be implicated in biological processes at
different stages of megakaryopoiesis and platelet
shedding.6 Genetic or induced (eg, by autoantibod-
ies) dysregulation of these PCD pathways may lead
to thrombocytopenia or ineffective thrompopoiesis
in ITP. The underlying mechanisms may act alone or
in concert, and their disentangling in future studies
may lead to novel therapeutic strategies and the
identification of patient subgroups that may benefit
from distinct treatment approaches.INTRINSIC AND EXTRINSIC APOPTOSIS OF
PLATELETS AND MEGAKARYOCYTES
Apoptosis is the physiologically most common
form of PCD. The anucleate platelets8,9 and mega-
karyocytes both possess a functional apoptotic
machinery, and an intrinsic program for apoptosis
that controls their survival and dictates their
lifespan.5,6 One of the major apoptotic pathways is
the so-called intrinsic (mitochondrial) apoptotic path-
way. The intrinsic pathway of apoptosis is tightly
regulated by members of the Bcl-2 protein family,
which contains both pro-death and pro-survival pro-
teins.10 The key mediators of intrinsic apoptosis,
Bak and Bax, if unrestrained, oligomerize in the
mitochondrial outer membrane, thereby inducing
mitochondrial outer membrane permeabilization
(MOMP), which results in the release of cytochrome
c and other soluble and apoptogenic proteins intop S109–S115 S109
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with apoptotic protease-activating factor 1 (APAF1)
and the initiator caspase, procaspase-9, to form the
apoptosome, which activates caspase-9 and down-
stream effector caspases.10 The activity of Bak and
Bax is tightly controlled by anti-apoptotic Bcl-2 family
members, of which Bcl-2, Bcl-xL, and Mcl-1 are
expressed in megakaryocytes.11 Bcl-xL and Mcl-1 have
been shown to coordinately regulate megakaryocyte
survival, whereas Mcl-1, but not Bcl-xL, seems dispen-
sable for platelet survival.8,11–13 A number of factors
have been shown to trigger the intrinsic pathway to
apoptosis in platelets, including chemical stimuli,
biomechanical rheological forces, and temperature.5
The so-called extrinsic pathway to apoptosis is
triggered by ligation of ‘‘death receptors’’ belonging
to the tumor necrosis factor (TNF) receptor super-
family that contain an intracellular death domain,
which can recruit and activate the initiator caspase,
procaspase-8. This leads to direct activation of down-
stream effector caspases by caspase-8, such as caspase-
3, -6, or -7.10 The extrinsic pathway can hence bypass
the Bcl-2 family and mitochondria. However, in some
cells (eg, hepatocytes, neutrophils) caspase-
8mediated cleavage of the pro-apoptotic BH3-only
protein Bid to its truncated form, tBid, has been
described, which leads to Bak- and Bax-dependent
MOMP.10,14,15 Although current evidence suggests
that megakaryocytes possess both intrinsic and extrin-
sic pathways to apoptosis, molecular and functional
aspects of the extrinsic pathway of apoptosis remain
to be explored in the megakaryocyte lineage.5,6PROCESS OF PLATELET PRODUCTION: A ROLE
FOR CASPASE-DEPENDENT PATHWAYS?
The process of platelet release involves the for-
mation of megakaryocyte cytoplasmic extensions
called proplatelets and intracellular membranes, so-
called demarcation membranes, which are probably
internal invaginations of the cytoplasmic membrane,
that eventually may serve as a membrane reservoir
for the generation of proplatelets.16 While proplate-
lets will engender functional platelets that are
released in the circulation, the remaining senescent
megakaryocyte body will remain in the bone marrow
as so-called denuded megakaryocyte, then undergo
apoptosis, and ultimately be phagocytosed by macro-
phages.17 Since the observation that platelet release
from megakaryocytes coincides with the onset of
apoptotic morphology,17,18 a significant body of
literature has been accumulated to support the view
that the apoptotic machinery is involved in the
complex cytoplasm reorganization events required
for platelet formation and shedding. De Botton
et al proposed that platelet formation involves com-
partmentalized and caspase-dependent apoptosis.19In another study, ligation of the death receptor Fas
(also called CD95) by either agonistic anti-Fas antibody
or soluble Fas resulted in a significant increase in
proplatelet extensions and production of functional
platelets.20 In both studies, the pan-caspase inhibitor
zVAD-fmk was employed to prove caspase-
dependence.19,20 Mice constitutively overexpressing
pro-survival Bcl-2 in hematopoietic cells,21 or lacking
the proapoptotic BH3-only protein Bim,22 exhibit mild
thrombocytopenia. Interestingly, thrombocytopenic
individuals with a mutation variant of cytochrome c,
ie, substitution of glycine by serine at residue 41
(G41S), which exhibits normal redox function but
enhanced pro-apoptotic activity, present with defec-
tive platelet formation.23 Electron microscopy of bone
marrow from these patients showed intramedullary
naked megakaryocyte nuclei and platelets, indicative
of dysregulated megakaryopoiesis with premature
release of platelets into the marrow space rather than
into sinusoids.
The concept that apoptosis is required for platelet
generation has been challenged by recent genetic
deletion or pharmacologic inhibition studies, which
showed that caspase-dependent pathways are dispen-
sable for platelet production, but instead might lead to
accelerated megakaryocyte death. In 2007, Mason et al
reported that loss of proapoptotic Bak and Bax pro-
longed platelet lifespan, but had no impact on platelet
production.8 In support of these data, Kozuma et al
showed that megakaryocytes of transgenic mice over-
expressing the prosurvival protein Bcl-2 exhibit normal
ability for in vitro platelet production; interestingly,
early megakaryocyte differentiation was impaired.24
Furthermore, mice with megakaryocyte-specific loss
of caspase-9 exhibited normal platelet counts and
functional platelets, as well as normal serum levels of
thrombopoietin (TPO), the major cytokine regulator of
megakaryopoiesis.25 Instead, caspase-9 was indispensa-
ble for apoptotic death of megakaryocytes and plate-
lets.25 Similarly, deletion of the prosurvival protein Bcl-
xL was shown to trigger megakaryocyte apoptosis
associated with failure of platelet production, a defect
that could be rescued by loss of Bak and Bax.11
Together, these data suggest that the intrinsic pathway
to apoptosis in megakaryocytes is not required for
platelet production, but rather initiates PCD.
The role of caspase-dependent pathways in the
generation of platelets by megakaryocytes remains to
be further explored. For instance, the possibility exists
that certain non-apoptotic functions of caspases are
required for platelet generation.11 Other proposed
explanations for the conflicting data relate to exper-
imental factors including the toxicity of the caspase
inhibitor zVAD-fmk in megakaryocytes,11 off-target
effects of overexpressed proteins or pharmacological
inhibitors (such as zVAD-fmk), and properties of
in vitro culture systems or cell lines.11,25
Cell death in ITP S111In view of the reported data, even if conflicting, it
is conceivable that aberrant blockade or activation of
apoptotic pathways in megakaryocytes may lead to
thrombocytopenia. Better insights into the molecu-
lar mechanisms that regulate platelet generation are
therefore required and might provide novel targets
for drug treatment in ITP or lead to the identification
of patient subgroups with a genetic defect of
thrombopoiesis, such as indicated by the example
of the cytochrome G41S mutation.23 Future studies
are urgently required to dissect the exact biochem-
ical pathways and enzymatic processes that contrib-
ute to megakaryocyte development and function at
different stages of megakaryopoiesis and platelet
shedding, including non-apoptotic or caspase-
dependent pathways, and even alternative cell death
pathways, such as autophagy and programmed
necrosis.6MEGAKARYOCYTE DEATH IN ITP
Morphological alterations of ITP megakaryocytes
in the bone marrow have been described by several
investigators and even before the infusion experi-
ment by Dr William Harrington in 1950.7 In a recent
ultrastructural study by Houwerzijl et al, ITP mega-
karyocytes were reported to exhibit cytoplasmic
vacuoles and ultrastructural features of apoptosis
and para-apoptosis.26 The percentage of damaged
megakaryocytes increased with advanced stages
of differentiation, and reached about 80% of mature
megakaryocytes in this study. Significantly fewer
immature megakaryocytes showed morphologic
alterations. The damaged cells were often sur-
rounded by macrophages and neutrophils,26 presum-
ably stimulating a phagocytotic response and an
inflammatory reaction, that is eventually evoked by
the non-apoptotic form of cell death. Exposure of
megakaryocytes from healthy individuals to ITP
plasma in vitro,26 or after transfusion in vivo,27 has
been shown to induce morphological alterations
compatible with (para-)apoptosis. It is possible that
premature elimination of maturing megakaryocytes,
before the initiation of platelet shedding, might lead
to ineffective thrombopoiesis rather than to an
absolute loss of total megakaryocyte mass. Such a
scenario would be compatible with the often normal
or even increased megakaryocyte numbers in the
bone marrow and the often unaltered plasma TPO
levels in ITP patients.PLATELET PHOSPHATIDYLSERINE
EXTERNALIZATION: A ROLE IN ITP?
Externalization of phosphatidylserine (PS) on the
surface of cells undergoing apoptosis represents the
most universal and best characterized ‘‘eat me’’signal that leads to recognition as ‘‘unwanted self’’
and clearance of the apoptotic cell by phago-
cytes.28,29 The translocation of PS from the inner to
the outer leaflet of the lipid bilayer occurs early in
the apoptotic process and involves a nonspecific
bidirectional phospholipid flip-flop along with the
blockade of an aminophospholipid translocase that
normally confines and reverts PS to the cytosolic side
of the cell membrane.29 Interestingly, PS exposure
also occurs on the cell surface of platelets upon
activation for the platelet to become procoagulant,
and to propagate the coagulation process by facili-
tating the assembly of coagulation factors and acti-
vation of tenase and prothrombinase complexes.30,31
The level of PS externalization during activation
seems to depend on the stimulus as a function of
the formation of a mitochondrial permeability tran-
sition pore (MPTP) or other induced molecular
pathways.32 Two distinct pathways appear to regu-
late platelet PS exposure: one calcium-dependent
and caspase-independent, and another Bak/Bax-
caspase-mediated pathway.33 Besides its procoagu-
lant function, PS exposure on activated platelets
might serve as a regulatory mechanism to avoid
potentially deleterious hyperactivity, and, for exam-
ple, initiate the systemic clearance of circulating
activated PS-positive cells by the reticulendothelial
system.
Abnormally increased PS exposure on patient
platelets has been reported for adult patients with
chronic ITP34 and for pediatric patients with acute
ITP.35 Winkler et al reported that the frequency of
platelets exposing PS was significantly higher in
children with acute ITP,35 and a significantly
higher proportion of ITP platelets contained acti-
vated capases-3, -9, and -8 compared to controls.35
Interestingly, the reported cleavage of caspase-8
suggests activation of the extrinsic, in conjunction
with the intrinsic, pathway of apoptosis. In the
chronic ITP study, both fresh and aged platelets
from patients exhibited significantly higher surface
PS levels compared to healthy donor platelets, as
assessed by flow cytometric annexin V-staining.34
In contrast to the study by Winkler et al,35 expo-
sure of PS appeared to be caspase-independent, but
no signs of activation (CD62P, CD154, PAC-1
expression) were found, suggesting that other
mechanisms for PS externalization might exist
in ITP.
Enhanced PS externalization on platelet surfaces
in ITP might lead to exceeding systemic clearance of
these cells by the reticuloendothelial system and
cause, or aggravate prevailing thrombocytopenia.
Future studies are required to support this concept
and to explore mechanisms of increased PS external-
ization, which might involve genetic differences
in molecular pathways that determine platelet
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hits inflicted by the circulatory environment,37 or
susceptibility to detriment caused by autoantibodies
or infectious particles.PRO-APOPTOTIC HUMORAL FACTORS IN ITP
The capacity of platelet surface molecules to
trigger platelet apoptosis has been reported for
glycoprotein (GP)IIb-IIIa and GPIba.5 GPIIbIIIa and
GPIba represent well known targets of platelet-
specific autoantibodies in ITP.3 Injection of rat anti-
mouse monoclonal antibody MWReg30, targeting
the GPIIb subunit of GPIIb-IIa, induced apoptosis
in mouse platelets in vivo and was associated with
marked thrombocytopenia.38 The injection of anti-
GPIIb resulted in platelet PS exposure, caspase-3
activation and mitochondrial inner transmembrane
potential depolarization.38 In another study, injec-
tion of rabbit polyclonal anti-platelet antibody
induced thrombocytopenia that was associated with
caspase-3 cleavage in platelets and could be pre-
vented by injection of the caspase inhibitor zVAD-
fmk.39 Given these data, it is conceivable that
proapoptotic platelet-specific autoantibodies con-
tribute to the abnormally increased PS exposure on
patient platelets observed in acute and chronic
ITP.34,35
It has been known for many decades that GPIIb-
IIIa and GPIb-IX are expressed on the surfaces of
megakaryocytes,40 and that anti-platelet and ITP
autoantibodies also bind to megakaryocytes.41–43 In
addition to the initiation of peripheral platelet
desctruction, several studies reported the capacity
of anti–GPIIb-IIIa and anti-GPIb antibodies in ITP
plasma to inhibit megakaryocyte production or
maturation, at least in a subpopulation of ITP
patients.44–46 In addition to genetic properties, the
susceptibility of a megakaryocyte for such suppres-
sion by these antibodies might depend on its matu-
ration stage.45
Besides platelet-specific autoantibodies, other
humoral factors in ITP plasma regulating lifespan of
megakaryocytes and platelets, megakaryopoiesis, or
platelet production, might be implicated in disease
pathogenesis. For instance, elevated levels of proa-
poptotic soluble Fas ligand were found in a sub-
group of adult patients with chronic ITP.47 Another
study reported aberrant levels of soluble tumor
necrosis factor-related apoptosis-inducing ligand
(TRAIL). Obviously, these effector molecules are less
specific than autoantibodies; however, given the
special role of apoptotic and PCD processes in
megakaryocytes and platelets,6 they might partici-
pate in certain disease processes, depending on
factors such as genetic characteristics, differentiation
stage and vulnerability of the target cell.CELL DEATH REGULATION BY INTRAVENOUS
IMMUNOGLOBULIN
Since the seminal observation reported by Paul
Imbach et al that intravenous immunoglobulin
(IVIG) treatment rapidly elevated platelet counts
in ITP,48 its therapeutic effect has been greatly
appreciated, and in current guidelines IVIG is still
considered a first-line therapy option for this indica-
tion.49,50 A number of different mechanisms have
been proposed that might eventually act in a mutu-
ally non-exclusive manner, including blocking
platelet-phagocytosis in the reticuloendothelial sys-
tem, FcgRIIB-mediated effects, and neutralization by
anti-idiotypic antibodies.51,52 Several studies also
suggest a potential role of IVIG in the regulation of
cell death of platelets and megakaryocytes. Winkler
et al reported that the pathologically increased
percentage of apoptotic platelets of children with
acute ITP is significantly reduced after IVIG treat-
ment.35 Interestingly, IVIG not only inhibited intrin-
sic, but also extrinsic, death receptor-dependent,
pathways of apoptosis, as revealed by cleavage of
caspase-8. An inhibitory effect of IVIG on platelet
apoptosis has also been shown by Leytin et al in an
animal model of ITP.38 Houwerzijl et al reported that
IVIG treatment significantly reduced the number of
para-apoptotic and apoptotic megakaryocytes and
increased the frequency of mature megakaryocytes
from 20% to 43%.26
IVIG preparations are derived from pooled plasma
of thousands of healthy donors and hence contain
the repertoire of the donor population. Studies
on IVIG have revealed that healthy individual pro-
duce autoantibodies with the capacity to balance
apoptotic processes of hematopoietic cells.53,54 Such
autoantibodies include agonistic antibodies to
Fas,55–57 Siglec-8,58 and Siglec-9,59 blocking antibod-
ies to Fas,55,60 and even anti-idiotypic antibodies to
Fas and Siglec-9.61 Whether quantitative or qualita-
tive dysregulation of these autoantibodies is impli-
cated in the pathogenesis in ITP remains to be
explored. However, therapeutic effects of IVIG in
toxic epidermal necrolysis (TEN) have been linked
to the presence of blocking anti-Fas antibodies in
IVIG.60 This study suggests that infusion of anti-
apoptotic antibodies may restore cellular homeo-
stasis in diseases associated with deregulated apop-
totic processes, including ITP.CONCLUSIONS
ITP is a diagnosis of exclusion. The variability in
natural history and response to therapy suggests that
ITP comprises heterogeneous disorders,62,63 which
might hence be regarded a syndrome.62 This notion
is supported by recent insights into the pathogenesis
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Figure 1. Putative mechanisms linked to cellular death pathways or phosphatidylserine exposure that might contribute to
the thrompocytopenia in immune thrombocytopenia (ITP) patients. Aberrant acceleration or inhibition of cellular death
pathways in the megakaryocyte lineage have been reported (see text) to initiate (1) premature death with phagocytic
clearance, to inhibit the (2) production or (3) differentiation of megakaryocytes, or to disorganize platelet shedding
processes, eventually associated with misdirected release of (4) immature or (5) mature platelets in the bone marrow.
Increased exposure of phosphatidylserine (PS), which acts as a so-called ‘‘eat-me signal’’ to initiate phagocytosis, occurs in
(6) apoptotic or (7) activated platelets, and has been observed on ITP platelets. Autoantibodies may induce PS expression
or facilitate the systemic clearance of PS-expressing platelets by the reticuloendothelial system. Art by Aldona von Gunten.
Cell death in ITP S113of ITP, derived from a broad range of experimental
studies focusing on different aspects of antibody- and
cell-mediated autoimmune responses.62,64,65 Here,
we discussed recent, and in part conflicting, evi-
dence, on the role of cell death pathways in a variety
of processes that might be implicated in the patho-
genesis of ITP (Figure 1). Genetic or acquired defects
of these pathways, or altered susceptibility to anti-
body- or cell-mediated apoptosis, might cause or
support thrombocytopenia in ITP, in processes
that include intramedullary apoptosis, ineffective
thrombopoiesis, and peripheral platelet destruction.
A better understanding of these mechanisms might
lead to novel therapeutic approaches and to a better
patient selection for the treatment of ITP.Acknowledgments
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